Is MF59-adjuvanted influenza vaccine (IV) a preferred priming vaccine for naive infants 6 – <24 months of age? A randomized controlled observer blind trial   


The objective is to determine if a priming vaccination schedule of with MF59-adjuvanted seasonal influenza vaccine followed by boosting immunization in the following year with unadjuvanted IV in infants induces superior serum hemagglutination inhibition (HI) antibody titers in year two compared to priming and boosting with unadjuvanted IV. We hypothesize that adjuvanted IV priming will result in higher anti-influenza antibody titers than unadjuvanted vaccine priming, and more robust cell mediated immune responses.

Project Lead:
Dr. Joanne Langley